2014•Yanke xinjinzhanRequires access

Recent advances in intravitreal injection of ranibizumab for myopic choroidal neovascularization

Bing Guo Lu

Abstract

Pathologic myopia is the second cause of choroidal neovascularization(CNV),after age-related macular degeneration,and the first cause in patients younger than 50 years.During recent years,anti-vascular endothelial growth factor drugs are now widely used not only to treat CNV in age-related macular degeneration but for myopic CNV,and show good results.This article reviews recent treatment advances in intravitreal injection of ranibizumab for myopic CNV.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ranibizumab, Macular degeneration, Choroidal neovascularization, Medicine, Ophthalmology, Optometry, Bevacizumab, Surgery